Experimental  ||| S:0 E:13 ||| JJ
mild  ||| S:13 E:18 ||| JJ
pulmonary  ||| S:18 E:28 ||| JJ
inflammation  ||| S:28 E:41 ||| NN
promotes  ||| S:41 E:50 ||| VBZ
the  ||| S:50 E:54 ||| DT
development  ||| S:54 E:66 ||| NN
of  ||| S:66 E:69 ||| IN
exercise-induced  ||| S:69 E:86 ||| JJ
pulmonary  ||| S:86 E:96 ||| NNS
haemorrhage  ||| S:96 E:108 ||| VBP
Histological  ||| S:108 E:121 ||| JJ
studies  ||| S:121 E:129 ||| NNS
of  ||| S:129 E:132 ||| IN
exercise-induced  ||| S:132 E:149 ||| JJ
pulmonary  ||| S:149 E:159 ||| JJ
haemorrhage  ||| S:159 E:171 ||| NNS
( ||| S:171 E:172 ||| -LRB-
EIPH ||| S:172 E:176 ||| NNP
)  ||| S:176 E:178 ||| -RRB-
reveals  ||| S:178 E:186 ||| VBZ
inflammatory  ||| S:186 E:199 ||| JJ
infiltrates  ||| S:199 E:211 ||| NN
within  ||| S:211 E:218 ||| IN
areas  ||| S:218 E:224 ||| NNS
of  ||| S:224 E:227 ||| IN
lung  ||| S:227 E:232 ||| NN
that  ||| S:232 E:237 ||| WDT
contain  ||| S:237 E:245 ||| VBP
haemorrhage ||| S:245 E:256 ||| VBN
.  ||| S:256 E:258 ||| .
This  ||| S:258 E:263 ||| DT
has  ||| S:263 E:267 ||| VBZ
resulted  ||| S:267 E:276 ||| VBN
in  ||| S:276 E:279 ||| IN
the  ||| S:279 E:283 ||| DT
hypothesis  ||| S:283 E:294 ||| NN
that  ||| S:294 E:299 ||| IN
pulmonary  ||| S:299 E:309 ||| JJ
inflammation  ||| S:309 E:322 ||| NN
could  ||| S:322 E:328 ||| MD
cause  ||| S:328 E:334 ||| VB
EIPH  ||| S:334 E:339 ||| NNP
or  ||| S:339 E:342 ||| CC
contribute  ||| S:342 E:353 ||| VB
to  ||| S:353 E:356 ||| TO
an  ||| S:356 E:359 ||| DT
increased  ||| S:359 E:369 ||| JJ
risk  ||| S:369 E:374 ||| NN
or  ||| S:374 E:377 ||| CC
severity  ||| S:377 E:386 ||| NN
of  ||| S:386 E:389 ||| IN
EIPH ||| S:389 E:393 ||| NNP
.  ||| S:393 E:395 ||| .
To  ||| S:395 E:398 ||| TO
determine  ||| S:398 E:408 ||| VB
whether  ||| S:408 E:416 ||| IN
experimentally-induced  ||| S:416 E:439 ||| JJ
pulmonary  ||| S:439 E:449 ||| NNS
inflammation  ||| S:449 E:462 ||| VBP
predisposes  ||| S:462 E:474 ||| VBG
the  ||| S:474 E:478 ||| DT
lung  ||| S:478 E:483 ||| NN
to  ||| S:483 E:486 ||| TO
haemorrhage  ||| S:486 E:498 ||| VB
during  ||| S:498 E:505 ||| IN
exercise ||| S:505 E:513 ||| NN
,  ||| S:513 E:515 ||| ,
by  ||| S:515 E:518 ||| IN
evaluating  ||| S:518 E:529 ||| VBG
the  ||| S:529 E:533 ||| DT
bronchoalveolar  ||| S:533 E:549 ||| JJ
lavage  ||| S:549 E:556 ||| NNS
( ||| S:556 E:557 ||| -LRB-
BAL ||| S:557 E:560 ||| NNP
)  ||| S:560 E:562 ||| -RRB-
cytology  ||| S:562 E:571 ||| NN
of  ||| S:571 E:574 ||| IN
normal  ||| S:574 E:581 ||| JJ
and  ||| S:581 E:585 ||| CC
inflamed  ||| S:585 E:594 ||| JJ
regions  ||| S:594 E:602 ||| NNS
of  ||| S:602 E:605 ||| IN
lung  ||| S:605 E:610 ||| NN
following  ||| S:610 E:620 ||| VBG
high  ||| S:620 E:625 ||| JJ
speed  ||| S:625 E:631 ||| NN
treadmill  ||| S:631 E:641 ||| NN
exercise ||| S:641 E:649 ||| NN
.  ||| S:649 E:651 ||| .
Transendoscopic  ||| S:651 E:667 ||| JJ
airway  ||| S:667 E:674 ||| JJ
inoculations  ||| S:674 E:687 ||| NN
of  ||| S:687 E:690 ||| IN
0.01 ||| S:690 E:694 ||| CD
%  ||| S:694 E:696 ||| NN
acetic  ||| S:696 E:703 ||| NN
acid  ||| S:703 E:708 ||| NN
were  ||| S:708 E:713 ||| VBD
used  ||| S:713 E:718 ||| VBN
to  ||| S:718 E:721 ||| TO
induce  ||| S:721 E:728 ||| VB
mild  ||| S:728 E:733 ||| JJ
localised  ||| S:733 E:743 ||| JJ
inflammation  ||| S:743 E:756 ||| NN
within  ||| S:756 E:763 ||| IN
bronchopulmonary  ||| S:763 E:780 ||| JJ
segments ||| S:780 E:788 ||| NNS
.  ||| S:788 E:790 ||| .
Horses  ||| S:790 E:797 ||| NNS
underwent  ||| S:797 E:807 ||| VBD
high  ||| S:807 E:812 ||| JJ
speed  ||| S:812 E:818 ||| NN
exercise  ||| S:818 E:827 ||| NN
24  ||| S:827 E:830 ||| CD
h  ||| S:830 E:832 ||| NN
after  ||| S:832 E:838 ||| IN
inoculation ||| S:838 E:849 ||| NN
.  ||| S:849 E:851 ||| .
Following  ||| S:851 E:861 ||| VBG
exercise ||| S:861 E:869 ||| NN
,  ||| S:869 E:871 ||| ,
inoculated  ||| S:871 E:882 ||| JJ
sites  ||| S:882 E:888 ||| NNS
and  ||| S:888 E:892 ||| CC
corresponding  ||| S:892 E:906 ||| JJ
segments  ||| S:906 E:915 ||| NNS
in  ||| S:915 E:918 ||| IN
the  ||| S:918 E:922 ||| DT
opposite  ||| S:922 E:931 ||| JJ
lung  ||| S:931 E:936 ||| NN
underwent  ||| S:936 E:946 ||| VBD
BAL ||| S:946 E:949 ||| NNP
.  ||| S:949 E:951 ||| .
The  ||| S:951 E:955 ||| DT
cytology  ||| S:955 E:964 ||| JJ
results  ||| S:964 E:972 ||| NNS
from  ||| S:972 E:977 ||| IN
inflamed  ||| S:977 E:986 ||| NN
and  ||| S:986 E:990 ||| CC
control  ||| S:990 E:998 ||| NN
bronchopulmonary  ||| S:998 E:1015 ||| NN
segments  ||| S:1015 E:1024 ||| NNS
were  ||| S:1024 E:1029 ||| VBD
compared ||| S:1029 E:1037 ||| VBN
,  ||| S:1037 E:1039 ||| ,
using  ||| S:1039 E:1045 ||| VBG
paired  ||| S:1045 E:1052 ||| VBN
t  ||| S:1052 E:1054 ||| JJ
tests ||| S:1054 E:1059 ||| NNS
.  ||| S:1059 E:1061 ||| .
Erythrocytes  ||| S:1061 E:1074 ||| NNP
were  ||| S:1074 E:1079 ||| VBD
present  ||| S:1079 E:1087 ||| JJ
in  ||| S:1087 E:1090 ||| IN
BAL  ||| S:1090 E:1094 ||| NNP
samples  ||| S:1094 E:1102 ||| NNS
from  ||| S:1102 E:1107 ||| IN
12.5 ||| S:1107 E:1111 ||| CD
%  ||| S:1111 E:1113 ||| NN
( ||| S:1113 E:1114 ||| -LRB-
1 ||| S:1114 E:1115 ||| CD
/ ||| S:1115 E:1116 ||| CD
8 ||| S:1116 E:1117 ||| CD
)  ||| S:1117 E:1119 ||| -RRB-
control  ||| S:1119 E:1127 ||| NN
segments  ||| S:1127 E:1136 ||| NNS
compared  ||| S:1136 E:1145 ||| VBN
with  ||| S:1145 E:1150 ||| IN
75 ||| S:1150 E:1152 ||| CD
%  ||| S:1152 E:1154 ||| NN
( ||| S:1154 E:1155 ||| -LRB-
6 ||| S:1155 E:1156 ||| CD
/ ||| S:1156 E:1157 ||| CD
8 ||| S:1157 E:1158 ||| CD
)  ||| S:1158 E:1160 ||| -RRB-
inoculated  ||| S:1160 E:1171 ||| JJ
segments  ||| S:1171 E:1180 ||| NNS
following  ||| S:1180 E:1190 ||| VBG
exercise ||| S:1190 E:1198 ||| NN
,  ||| S:1198 E:1200 ||| ,
indicating  ||| S:1200 E:1211 ||| VBG
a  ||| S:1211 E:1213 ||| DT
significant  ||| S:1213 E:1225 ||| JJ
increase  ||| S:1225 E:1234 ||| NN
( ||| S:1234 E:1235 ||| -LRB-
P  ||| S:1235 E:1237 ||| NN
=  ||| S:1237 E:1239 ||| SYM
0.04 ||| S:1239 E:1243 ||| CD
)  ||| S:1243 E:1245 ||| -RRB-
in  ||| S:1245 E:1248 ||| IN
the  ||| S:1248 E:1252 ||| DT
relative  ||| S:1252 E:1261 ||| JJ
risk  ||| S:1261 E:1266 ||| NN
of  ||| S:1266 E:1269 ||| IN
EIPH  ||| S:1269 E:1274 ||| NNP
following  ||| S:1274 E:1284 ||| VBG
the  ||| S:1284 E:1288 ||| DT
development  ||| S:1288 E:1300 ||| NN
of  ||| S:1300 E:1303 ||| IN
pulmonary  ||| S:1303 E:1313 ||| JJ
inflammation ||| S:1313 E:1325 ||| NN
.  ||| S:1325 E:1327 ||| .
Samples  ||| S:1327 E:1335 ||| NNS
from  ||| S:1335 E:1340 ||| IN
inoculated  ||| S:1340 E:1351 ||| JJ
segments  ||| S:1351 E:1360 ||| NNS
had  ||| S:1360 E:1364 ||| VBD
significantly  ||| S:1364 E:1378 ||| RB
higher  ||| S:1378 E:1385 ||| JJR
percentages  ||| S:1385 E:1397 ||| NNS
and  ||| S:1397 E:1401 ||| CC
numbers  ||| S:1401 E:1409 ||| NNS
of  ||| S:1409 E:1412 ||| IN
neutrophils  ||| S:1412 E:1424 ||| NNS
( ||| S:1424 E:1425 ||| -LRB-
12.1  ||| S:1425 E:1430 ||| CD
±  ||| S:1430 E:1432 ||| CD
1.0 ||| S:1432 E:1435 ||| CD
%  ||| S:1435 E:1437 ||| NN
and  ||| S:1437 E:1441 ||| CC
601  ||| S:1441 E:1445 ||| CD
±  ||| S:1445 E:1447 ||| CD
98  ||| S:1447 E:1450 ||| CD
cells ||| S:1450 E:1455 ||| CD
/ ||| S:1455 E:1456 ||| CD
μl ||| S:1456 E:1458 ||| CD
)  ||| S:1458 E:1460 ||| -RRB-
than  ||| S:1460 E:1465 ||| IN
control  ||| S:1465 E:1473 ||| NN
samples  ||| S:1473 E:1481 ||| NNS
( ||| S:1481 E:1482 ||| -LRB-
4.3  ||| S:1482 E:1486 ||| CD
±  ||| S:1486 E:1488 ||| CD
0.3 ||| S:1488 E:1491 ||| CD
%  ||| S:1491 E:1493 ||| NN
and  ||| S:1493 E:1497 ||| CC
214  ||| S:1497 E:1501 ||| CD
±  ||| S:1501 E:1503 ||| CD
52  ||| S:1503 E:1506 ||| CD
cells ||| S:1506 E:1511 ||| CD
/ ||| S:1511 E:1512 ||| CD
μl ||| S:1512 E:1514 ||| CD
) ||| S:1514 E:1515 ||| -RRB-
.  ||| S:1515 E:1517 ||| .
Significantly  ||| S:1517 E:1531 ||| RB
higher  ||| S:1531 E:1538 ||| RBR
erythrocyte  ||| S:1538 E:1550 ||| JJ
numbers  ||| S:1550 E:1558 ||| NNS
were  ||| S:1558 E:1563 ||| VBD
observed  ||| S:1563 E:1572 ||| VBN
in  ||| S:1572 E:1575 ||| IN
samples  ||| S:1575 E:1583 ||| NNS
from  ||| S:1583 E:1588 ||| IN
inoculated  ||| S:1588 E:1599 ||| JJ
segments  ||| S:1599 E:1608 ||| NNS
( ||| S:1608 E:1609 ||| -LRB-
14,304  ||| S:1609 E:1616 ||| FW
±  ||| S:1616 E:1618 ||| FW
6862  ||| S:1618 E:1623 ||| FW
cells ||| S:1623 E:1628 ||| FW
/ ||| S:1628 E:1629 ||| FW
μl ||| S:1629 E:1631 ||| FW
)  ||| S:1631 E:1633 ||| -RRB-
compared  ||| S:1633 E:1642 ||| VBN
with  ||| S:1642 E:1647 ||| IN
control  ||| S:1647 E:1655 ||| NN
samples  ||| S:1655 E:1663 ||| NNS
( ||| S:1663 E:1664 ||| -LRB-
3.5  ||| S:1664 E:1668 ||| CD
±  ||| S:1668 E:1670 ||| CD
3.5  ||| S:1670 E:1674 ||| CD
cells ||| S:1674 E:1679 ||| CD
/ ||| S:1679 E:1680 ||| CD
μl ||| S:1680 E:1682 ||| CD
) ||| S:1682 E:1683 ||| -RRB-
.  ||| S:1683 E:1685 ||| .
The  ||| S:1685 E:1689 ||| DT
results  ||| S:1689 E:1697 ||| NNS
showed  ||| S:1697 E:1704 ||| VBD
inflammation  ||| S:1704 E:1717 ||| VBN
increased  ||| S:1717 E:1727 ||| VBN
the  ||| S:1727 E:1731 ||| DT
risk  ||| S:1731 E:1736 ||| NN
of  ||| S:1736 E:1739 ||| IN
developing  ||| S:1739 E:1750 ||| VBG
pulmonary  ||| S:1750 E:1760 ||| JJ
haemorrhage  ||| S:1760 E:1772 ||| NN
during  ||| S:1772 E:1779 ||| IN
exercise ||| S:1779 E:1787 ||| NN
.  ||| S:1787 E:1789 ||| .
These  ||| S:1789 E:1795 ||| DT
findings  ||| S:1795 E:1804 ||| NNS
do  ||| S:1804 E:1807 ||| VBP
not  ||| S:1807 E:1811 ||| RB
conflict  ||| S:1811 E:1820 ||| NN
with  ||| S:1820 E:1825 ||| IN
current  ||| S:1825 E:1833 ||| JJ
theories  ||| S:1833 E:1842 ||| NNS
on  ||| S:1842 E:1845 ||| IN
the  ||| S:1845 E:1849 ||| DT
common  ||| S:1849 E:1856 ||| JJ
causes  ||| S:1856 E:1863 ||| NNS
of  ||| S:1863 E:1866 ||| IN
EIPH ||| S:1866 E:1870 ||| NNP
,  ||| S:1870 E:1872 ||| ,
but  ||| S:1872 E:1876 ||| CC
suggest  ||| S:1876 E:1884 ||| VB
that  ||| S:1884 E:1889 ||| DT
care  ||| S:1889 E:1894 ||| NN
should  ||| S:1894 E:1901 ||| MD
be  ||| S:1901 E:1904 ||| VB
taken  ||| S:1904 E:1910 ||| VBN
when  ||| S:1910 E:1915 ||| WRB
recommending  ||| S:1915 E:1928 ||| VBG
exercise  ||| S:1928 E:1937 ||| NN
in  ||| S:1937 E:1940 ||| IN
horses  ||| S:1940 E:1947 ||| NNS
suspected  ||| S:1947 E:1957 ||| VBN
to  ||| S:1957 E:1960 ||| TO
be  ||| S:1960 E:1963 ||| VB
suffering  ||| S:1963 E:1973 ||| VBG
from  ||| S:1973 E:1978 ||| IN
pulmonary  ||| S:1978 E:1988 ||| JJ
inflammatory  ||| S:1988 E:2001 ||| JJ
disease ||| S:2001 E:2008 ||| NN
.  ||| S:2008 E:2010 ||| .
In  ||| S:2010 E:2013 ||| IN
addition ||| S:2013 E:2021 ||| NN
,  ||| S:2021 E:2023 ||| ,
specific  ||| S:2023 E:2032 ||| JJ
therapy  ||| S:2032 E:2040 ||| NN
to  ||| S:2040 E:2043 ||| TO
reduce  ||| S:2043 E:2050 ||| VB
pulmonary  ||| S:2050 E:2060 ||| JJ
inflammation  ||| S:2060 E:2073 ||| NN
may  ||| S:2073 E:2077 ||| MD
benefit  ||| S:2077 E:2085 ||| VB
horses  ||| S:2085 E:2092 ||| NNS
prone  ||| S:2092 E:2098 ||| JJ
to  ||| S:2098 E:2101 ||| TO
the  ||| S:2101 E:2105 ||| DT
development  ||| S:2105 E:2117 ||| NN
of  ||| S:2117 E:2120 ||| IN
EIPH ||| S:2120 E:2124 ||| NNP
.  ||| S:2124 E:2126 ||| .
